International Journal of Hematology

, Volume 83, Issue 1, pp 80–85 | Cite as

Mycophenolate Mofetil Is Effective and Well Tolerated in the Treatment of Refractory Acute and Chronic Graft-versus-Host Disease

  • Akiyoshi Takami
  • Kanako Mochizuki
  • Hirokazu Okumura
  • Hirohito Yamazaki
  • Masahide Yamazaki
  • Yukio Kondo
  • Hidesaku Asakura
  • Shinji Nakao
  • Satsuki Ito
  • Yukio Suga


We enrolled 11 patients with refractory graft-versus-host disease (GVHD) in a prospective trial evaluating the efficacy of mycophenolate mofetil (MMF). Four (67%) of the 6 patients with acute GVHD and all 5 patients with chronic GVHD responded to MMF. Ten (91%) of the 11 patients were able to decrease steroid use (median decrease, 86%; range, 25%-100%). After a median follow-up of 18 months (range, 1-65 months), 7 patients (64%) remained alive. The adverse events were infectious complications (36%), diarrhea (27%), and neutropenia (18%); the only patient discontinuing MMF did so because of grade 4 neutropenia. This preliminary study suggests that MMF is a well-tolerated agent and has a beneficial effect in the treatment of refractory acute and chronic GVHD.

Key words

Mycophenolate mofetil Allogeneic stem cell transplantation Mismatched donor Graft-versus-host disease 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Martin PJ, Schoch G, Fisher L et al. A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. Blood. 1991;77:1821–1828.PubMedGoogle Scholar
  2. 2.
    Furlong T, Storb R, Anasetti C, et al. Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities. Bone Marrow Transplant. 2000;26:985–991.CrossRefPubMedGoogle Scholar
  3. 3.
    Carnevale-Schianca F, Martin P, Sullivan K et al.. Changing from cyclosporine to tacrolimus as salvage therapy for chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2000;6:613–620.CrossRefPubMedGoogle Scholar
  4. 4.
    Sullivan KM, Witherspoon RP, Storb R, et al. Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease. Blood. 1988;72:555–561.PubMedGoogle Scholar
  5. 5.
    Wingard JR, Piantadosi S, Vogelsang GB, et al. Predictors of death from chronic graft-versus-host disease after bone marrow transplantation. Blood. 1989;74:1428–1435.PubMedGoogle Scholar
  6. 6.
    Bolanos-Meade J, Vogelsang GB. Novel strategies for steroid-refractory acute graft-versus-host disease. Curr Opin Hematol. 2005;12:40–44.CrossRefPubMedGoogle Scholar
  7. 7.
    Devetten MP, Vose JM. Graft-versus-host disease: how to translate new insights into new therapeutic strategies. Biol Blood Marrow Transplant. 2004;10:815–825.CrossRefPubMedGoogle Scholar
  8. 8.
    Antin JH, Chen AR, Couriel DR, Ho VT, Nash RA, Weisdorf D. Novel approaches to the therapy of steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant. 2004;10:655–668.CrossRefPubMedGoogle Scholar
  9. 9.
    Martin PJ, Carpenter PA, Sanders JE, Flowers ME. Diagnosis and clinical management of chronic graft-versus-host disease. Int J Hematol. 2004;79:221–228.CrossRefPubMedGoogle Scholar
  10. 10.
    Socie G. Chronic graft-versus-host disease: clinical features and grading systems. Int J Hematol. 2004;79:216–220.CrossRefPubMedGoogle Scholar
  11. 11.
    Bacigalupo A, Palandri F. Management of acute graft versus host disease (GvHD). Hematol J. 2004;5:189–196.CrossRefPubMedGoogle Scholar
  12. 12.
    Mookerjee B, Altomonte V, Vogelsang G. Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus. Bone Marrow Transplant. 1999;24:517–520.CrossRefPubMedGoogle Scholar
  13. 13.
    Allison AC, Eugui EM. Purine metabolism and immunosuppres-sive effects of mycophenolate mofetil (MMF). Clin Transplant. 1996;10:77–84.PubMedGoogle Scholar
  14. 14.
    Lipsky JJ. Mycophenolate mofetil. Lancet. 1996;348:1357–1359.CrossRefPubMedGoogle Scholar
  15. 15.
    European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet. 1995;345:1321–1325.CrossRefGoogle Scholar
  16. 16.
    Basara N, Blau WI, Kiehl MG, et al. Efficacy and safety of mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant recipient. Transplant Proc. 1998;30:4087–4089.CrossRefPubMedGoogle Scholar
  17. 17.
    Basara N, Blau WI, Romer E, et al. Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients. Bone Marrow Transplant. 1998;22:61–65.CrossRefPubMedGoogle Scholar
  18. 18.
    Busca A, Saroglia EM, Lanino E, et al. Mycophenolate mofetil (MMF) as therapy for refractory chronic GVHD (cGVHD) in children receiving bone marrow transplantation. Bone Marrow Transplant. 2000;25:1067–1071.CrossRefPubMedGoogle Scholar
  19. 19.
    Basara N, Kiehl MG, Blau W, et al. Mycophenolate mofetil in the treatment of acute and chronic GVHD in hematopoietic stem cell transplant patients: four years of experience. Transplant Proc. 2001;33:2121–2123.CrossRefPubMedGoogle Scholar
  20. 20.
    Baudard M, Vincent A, Moreau P, Kergueris MF, Harousseau JL, Milpied N. Mycophenolate mofetil for the treatment of acute and chronic GVHD is effective and well tolerated but induces a high risk of infectious complications: a series of 21 BM or PBSC transplant patients. Bone Marrow Transplant. 2002;30:287–295.CrossRefPubMedGoogle Scholar
  21. 21.
    Busca A, Locatelli F, Marmont F, Audisio E, Falda M. Response to mycophenolate mofetil therapy in refractory chronic graft-versus-host disease. Haematologica. 2003;88:837–839.PubMedGoogle Scholar
  22. 22.
    Kim JG, Sohn SK, Kim DH, et al. Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant. EurJ Haematol. 2004;73:56–61.CrossRefGoogle Scholar
  23. 23.
    Lopez F, Parker P, Nademanee A, et al. Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2005;11:307–313.CrossRefPubMedGoogle Scholar
  24. 24.
    Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man: a long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69:204–217.CrossRefPubMedGoogle Scholar
  25. 25.
    Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15:825–828.PubMedGoogle Scholar
  26. 26.
    Hambach L, Stadler M, Dammann E, Ganser A, Hertenstein B. Increased risk of complicated CMV infection with the use of mycophenolate mofetil in allogeneic stem cell transplantation. Bone Marrow Transplant. 2002;29:903–906.CrossRefPubMedGoogle Scholar
  27. 27.
    Shapira MY, Hirshfeld E, Weiss L, et al. Mycophenolate mofetil does not suppress the graft-versus-leukemia effect or the activity of lymphokine-activated killer (LAK) cells in a murine model. Cancer Immunol Immunother. 2005;54:383–388.CrossRefPubMedGoogle Scholar
  28. 28.
    Weiss L, Reich S, Slavin S. Effect of cyclosporine A and methyl-prednisolone on the graft-versus-leukemia effects across major his-tocompatibility barriers in mice following allogeneic bone marrow transplantation. Bone Marrow Transplant. 1990;6:229–233.PubMedGoogle Scholar
  29. 29.
    Bacigalupo A, van Lint MT, Occhini D, et al. Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia. Blood. 1991;77:1423–1428.PubMedGoogle Scholar
  30. 30.
    Hiraoka A, Ohashi Y, Okamoto S, et al. for the Japanese FK506 BMT Study Group. Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation. Bone Marrow Transplant. 2001;28:181–185.CrossRefPubMedGoogle Scholar
  31. 31.
    Ruutu T, Hermans J, Niederwieser D, et al. Thrombotic thrombo- cytopenic purpura after allogeneic stem cell transplantation: a survey of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol. 2002;118:1112–1119.CrossRefPubMedGoogle Scholar
  32. 32.
    Antin JH, Kim HT, Cutler C, et al. Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood. 2003;102:1601–1605.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2006

Authors and Affiliations

  • Akiyoshi Takami
    • 1
  • Kanako Mochizuki
    • 1
  • Hirokazu Okumura
    • 1
  • Hirohito Yamazaki
    • 1
  • Masahide Yamazaki
    • 1
  • Yukio Kondo
    • 1
  • Hidesaku Asakura
    • 1
  • Shinji Nakao
    • 1
  • Satsuki Ito
    • 2
  • Yukio Suga
    • 2
  1. 1.Department of Cellular Transplantation BiologyKanazawa University Graduate School of MedicineKanazawa, IshikawaJapan
  2. 2.Department of PharmacyKanazawa University Graduate School of MedicineKanazawaJapan

Personalised recommendations